Pulmonx Corporation $LUNG Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its position in Pulmonx Corporation (NASDAQ:LUNG) by 32.1% during the second quarter, HoldingsChannel.com reports. The fund owned 218,758 shares of the company’s stock after acquiring an additional 53,148 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Pulmonx were worth $567,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new stake in Pulmonx during the second quarter worth $84,000. Corton Capital Inc. purchased a new stake in shares of Pulmonx in the 2nd quarter worth about $32,000. Bank of Montreal Can purchased a new stake in shares of Pulmonx in the 2nd quarter worth about $53,000. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in Pulmonx in the 2nd quarter valued at about $197,000. Finally, R Squared Ltd purchased a new position in Pulmonx during the 2nd quarter valued at about $41,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Stock Down 1.4%

LUNG stock opened at $1.38 on Thursday. The company has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $2.29. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The stock has a market capitalization of $56.93 million, a P/E ratio of -0.98 and a beta of 0.44. Pulmonx Corporation has a one year low of $1.35 and a one year high of $9.37.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $20.78 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. Pulmonx has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pulmonx Corporation will post -1.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LUNG. Wells Fargo & Company reduced their price target on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Lake Street Capital reduced their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Stifel Nicolaus dropped their price target on Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.81.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.